CDC-RFA-CK22-2202: Continuing Enhanced National Surveillance for Prion Diseases in the United States
Closed
This grant is closed. A newer notice from the same program is forecast: Continuing Enhanced National Surveillance for Prion Diseases in the United States (CDC-RFA-CK-27-0046). Status: Expected deadline March 27, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2022.
Centers for Disease Control - NCEZID offered grants to any type of organization. It expected to make one award worth $20.0 million in total. Applications closed on March 29, 2022.
From the official notice on Grants.gov, last changed January 28, 2022. Checked November 7, 2026.
- Total funding$20.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| CDC-RFA-CK-27-0046 | July 10, 2026 | Expected deadline March 27, 2027 | Forecast |
Key dates
| Posted | January 28, 2022 |
|---|---|
| Deadline | March 29, 2022 |
| Archived by Grants.gov | April 28, 2022 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Hospitals, Laboratories and other public and/or private entities may apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2022 funds for a cooperative agreement program to continue enhanced national surveillance for human prion diseases in the United States. The purpose of the funding is to continue an active surveillance program similar to that conducted by the National Prion Disease Pathology Surveillance Center (NPDPSC) since 1997 to monitor the occurrence of potentially emerging human transmissible spongiform encephalopathies (TSEs) in the United States. In 1997, in collaboration with the American Association of Neuropathologists (AANP), the National Prion Disease Pathology Surveillance Center was established to enhance national CJD surveillance and to make possible laboratory investigation of newly emerging prion diseases. This pathology center, currently located at Case Western Reserve University in Cleveland, Ohio, provided the services of a cutting edge prion disease laboratory, filling a critical public health gap for monitoring prion diseases in humans. Brain tissues and clinical laboratory information on clinically suspected and diagnosed cases of human prion disease have been evaluated at the NPDPSC for approximately 20 years to confirm diagnoses and determine the type of prion disease, including whether the patients had variant CJD or some other possible emerging prion disease in the United States.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death by Infectious Diseases (93.084) awarded $241 million across 128 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Puerto Rico Science, Technology, and Research Trust | Puerto Rico | 4 | $14.5 million |
| Massachusetts Department of Public Health | Massachusetts | 1 | $11.6 million |
| Emory University | Georgia | 3 | $11.5 million |
| Uganda Virus Research Institute | 1 | $8.7 million | |
| Ponce Medical School Foundation Inc | Puerto Rico | 2 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-CK-27-0046, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK22-2202 still open?
No. It closed on March 29, 2022. A newer notice is forecast: CDC-RFA-CK-27-0046, expected deadline March 27, 2027.
Who can apply for Continuing Enhanced National Surveillance for Prion Diseases in the United States?
Centers for Disease Control - NCEZID accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Continuing Enhanced National Surveillance for Prion Diseases in the United States?
Closed March 29, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $20.0 million in total for one award.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before?
The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)